O'Leary James J 4

4 · Fusion Pharmaceuticals Inc. · Filed Jun 30, 2020

Form 4

Period: 2020-06-25

Chief Medical Officer

Transactions

Award
Stock Option (Right to Buy)
2020-03-16+351,921→ 351,921 total
Exercise: $4.44Exp: 2030-03-16→ Non-Voting Common Shares (351,921 underlying)
Award
Stock Option (Right to Buy)
2020-06-25+60,852→ 60,852 total
Exercise: $17.00Exp: 2030-06-25→ Common Shares (60,852 underlying)
Award
Stock Option (Right to Buy)
2020-06-25+26,971→ 26,971 total
Exercise: $17.00Exp: 2030-06-18→ Common Shares (26,971 underlying)

Footnotes (3)

[F1]25% of the shares subject to this option shall vest and become exercisable on March 16, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter. Prior to closing of the Issuer's initial public offering, such Non-Voting Common Shares will convert into Voting Common Shares and subsequently into Common Shares on a one-for-one basis.
[F2]25% of the shares subject to this option shall vest and become exercisable on June 18, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
[F3]25% of the shares subject to this option shall vest and become exercisable on June 25, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Documents

1 file